The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly
because of the expanding indications for standard-of-care treatment and the development of …

Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …

Chimeric antigen receptor (CAR) therapy has had a transformative effect on the treatment of
haematologic malignancies,,,,–, but it has shown limited efficacy against solid tumours. Solid …

Abstract CD4+ T cells and CD4+ chimeric antigen receptor (CAR) T cells display highly
variable antitumor activity in preclinical models and in patients; however, the mechanisms …

Background T cell mediated hyperinflammatory responses such as cytokine release
syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) are …

Acute myeloid leukemia (AML) poses a singular challenge for chimeric antigen receptor
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …

Previous studies have developed vascularized tumor spheroid models to demonstrate the
impact of intravascular flow on tumor progression and treatment. However, these models …

Autologous anti-CD19 chimeric antigen receptor T cell (CAR T) therapy is highly effective in
relapsed/refractory large B cell lymphoma (rrLBCL) but is associated with toxicities that …

The in vivo persistence of adoptively transferred T cells is predictive of antitumor response.
Identifying functional properties of infused T cells that lead to in vivo persistence and tumor …

In the past decade, the emergence of chimeric antigen receptor (CAR) T-cell therapy has led
to a cellular immunotherapy revolution against various cancers. Although CAR-T cell …